[{"orgOrder":0,"company":"ImmunogenX","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Latiglutenase","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"ImmunogenX","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ImmunogenX \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ImmunogenX \/ Not Applicable"},{"orgOrder":0,"company":"ImmunogenX","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Latiglutenase","moa":"Gluten","graph1":"Gastroenterology","graph2":"Phase II","graph3":"ImmunogenX","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ImmunogenX \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"ImmunogenX \/ National Institutes of Health"},{"orgOrder":0,"company":"ImmunogenX","sponsor":"Mayo Clinic","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Latiglutenase","moa":"Gluten","graph1":"Gastroenterology","graph2":"Phase II","graph3":"ImmunogenX","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"ImmunogenX \/ Mayo Clinic","highestDevelopmentStatusID":"8","companyTruncated":"ImmunogenX \/ Mayo Clinic"},{"orgOrder":0,"company":"ImmunogenX","sponsor":"First Wave BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Merger","leadProduct":"Latiglutenase","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"ImmunogenX","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"ImmunogenX \/ First Wave BioPharma","highestDevelopmentStatusID":"8","companyTruncated":"ImmunogenX \/ First Wave BioPharma"},{"orgOrder":0,"company":"ImmunogenX","sponsor":"First Wave BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Merger","leadProduct":"Latiglutenase","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"ImmunogenX","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"ImmunogenX \/ First Wave BioPharma","highestDevelopmentStatusID":"8","companyTruncated":"ImmunogenX \/ First Wave BioPharma"}]

Find Clinical Drug Pipeline Developments & Deals by ImmunogenX

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : Through acquisition, First Wave advances its lead product IMGX003 (latiglutenase) for treating celiac disease, currently under Phase II clinical trials.

                          Brand Name : IMGX003

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          March 14, 2024

                          Lead Product(s) : Latiglutenase

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase II

                          Sponsor : First Wave BioPharma

                          Deal Size : Undisclosed

                          Deal Type : Merger

                          blank

                          02

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : Through the acquisition, First Wave will advance its lead product candidate IMGX003 (latiglutenase) for research & development and commercialization purposes. Currently, it is being evaluated in Phase II clinical trial studies for the treatment of Celiac...

                          Brand Name : IMGX003

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          December 18, 2023

                          Lead Product(s) : Latiglutenase

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase II

                          Sponsor : First Wave BioPharma

                          Deal Size : Undisclosed

                          Deal Type : Merger

                          blank

                          03

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : The company is developing latiglutenase (IMGX003) for celiac disease therapy. ImmunogenX is also developing a diagnostic tool for celiac disease management as a minimally-invasive monitor of villus health to follow the state of recovery of a celiac patie...

                          Brand Name : IMGX003

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          August 12, 2022

                          Lead Product(s) : Latiglutenase

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase II

                          Sponsor : Mayo Clinic

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : CeliacShield Trial is a double-blind, placebo controlled, gluten challenge trial of the efficacy, safety and tolerability of 6-weeks treatment of Latiglutenase (IMGX003) administration in patients with well-controlled celiac disease.

                          Brand Name : IMGX003

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          March 18, 2021

                          Lead Product(s) : Latiglutenase

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase II

                          Sponsor : National Institutes of Health

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : The trial will test the safety and efficacy of the company’s lead therapeutic candidate, Latiglutenase (IMGX003).

                          Brand Name : Undisclosed

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          February 13, 2020

                          Lead Product(s) : Latiglutenase

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank